Drug profile · INN
metoprolol succinate
METOPROLOL SUCCINATE
metoprolol succinate (METOPROLOL SUCCINATE) is a beta-1 adrenergic receptor antagonist. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: oral. Current US regulatory status: approved.
Drug details — metoprolol succinate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
metoprolol succinate (METOPROLOL SUCCINATE) is a beta-1 adrenergic receptor antagonist. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-1 adrenergic receptor antagonist
Primary target: Beta-1 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is metoprolol succinate?
metoprolol succinate (METOPROLOL SUCCINATE) is a beta-1 adrenergic receptor antagonist. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for metoprolol succinate?
METOPROLOL SUCCINATE is a marketed brand name for metoprolol succinate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of metoprolol succinate?
metoprolol succinate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.